



California State Board of Pharmacy
2720 Gateway Oaks Drive, Suite 100
Sacramento, CA 95833
Phone: (916) 518-3100 Fax: (916) 574-8618
www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency
Department of Consumer Affairs
Gavin Newsom, Governor



To: Board Members

Subject: Executive Officer Report

Medication Error Reporting Request for Proposal

As part of its implementation activities related to Assembly Bill 1286 (Haney, Chapter 470, Statutes of 2023) the Board must approve an entity to receive and review medication error reports consistent with the requirements established in Business and Professions Code (BPC) section 4113.1. In anticipation of significant interest from entities interested in serving as this entity, as part of the Enforcement and Compounding Committee's January 2024 meeting, a presentation was provided on the state contracting process. (**Note:** The livestream of the meeting and presentation slides are available on the Board's website.) Further, during the February 8, 2024 Board meeting, the Board finalized parameters for the reporting requirements and appointed Maria Serpa to serve on the panel responsible for review of proposals and selection of a vendor to serve as the Board's approved entity.

Since that time, staff and DCA have worked to finalize the Request for Proposal (RFP). On July 20, 2024, the RFP was [posted](#) on Cal eProcure. Consistent with the provisions of the statute, as part of the September 12, 2024 Board meeting, it is anticipated the Board will consider a vendor for approval.

Changes to the CURES System

The California Department of Justice announced a transition to a newer version of ASAP v4.2B effective August 1, 2024. The Board has taken measures to ensure impacted licensees are aware of this transition, including posting information on the homepage of the Board's [website](#), releasing subscriber alerts, and providing updates on the Board's social media account.

New Learning Management System

The Board provides a number of training programs on its website, including some mandatory trainings. The Board recently secured a new learning management system (LMS) to deploy its online training programs. It is anticipated that the transition to the new platform will be completed by the end of the year. (**Note:** The Board's prior platform to manage completion of these training programs no longer supports features necessary to confirm completion of the trainings.) The Board is exploring a process to award continuing education to individuals attending Board and committee meetings through the new LMS. Future agendas will include information on the process.

American Society of Addiction Medicine

On July 18, 2024, the American Society of Addiction Medicine released a [public policy statement](#), "The Role of Pharmacists in Medications for Addiction Treatment." The policy statement supports pharmacists' role in ensuring the safe and effective use of addiction medications, including buprenorphine. While some of the recommendations included in the statement are inconsistent with the Board's position, many of the sentiments conveyed in the policy statement are consistent with the Board's support of pharmacists engaging as providers in the treatment of substance use disorders. Further, the policy statement highlights some of the barriers faced by pharmacists including reimbursement and supply chain challenges.